Advances in understanding and managing bullous pemphigoid

Bullous pemphigoid (BP) is the commonest subtype of autoimmune blistering disease in most countries of the world. It occurs most frequently in elderly patients and is characterised clinically by large, tense blisters in the skin preceded by urticarial plaques and pruritus. Immunopathologically, it i...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Cathy Y., Murrell, Dedee F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754018/
https://www.ncbi.nlm.nih.gov/pubmed/26918143
http://dx.doi.org/10.12688/f1000research.6896.1
_version_ 1782415961772523520
author Zhao, Cathy Y.
Murrell, Dedee F.
author_facet Zhao, Cathy Y.
Murrell, Dedee F.
author_sort Zhao, Cathy Y.
collection PubMed
description Bullous pemphigoid (BP) is the commonest subtype of autoimmune blistering disease in most countries of the world. It occurs most frequently in elderly patients and is characterised clinically by large, tense blisters in the skin preceded by urticarial plaques and pruritus. Immunopathologically, it is characterised by autoantibodies directed against the 180 kD antigen (BP180) and the 230 kD antigen (BP230). New knowledge regarding BP is being continually uncovered. This article reviews the recent advances in BP, including newer diagnostic tests, standardised outcome measures and emerging therapeutic options, as well as the evidence supporting their use.
format Online
Article
Text
id pubmed-4754018
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-47540182016-02-24 Advances in understanding and managing bullous pemphigoid Zhao, Cathy Y. Murrell, Dedee F. F1000Res Review Bullous pemphigoid (BP) is the commonest subtype of autoimmune blistering disease in most countries of the world. It occurs most frequently in elderly patients and is characterised clinically by large, tense blisters in the skin preceded by urticarial plaques and pruritus. Immunopathologically, it is characterised by autoantibodies directed against the 180 kD antigen (BP180) and the 230 kD antigen (BP230). New knowledge regarding BP is being continually uncovered. This article reviews the recent advances in BP, including newer diagnostic tests, standardised outcome measures and emerging therapeutic options, as well as the evidence supporting their use. F1000Research 2015-11-20 /pmc/articles/PMC4754018/ /pubmed/26918143 http://dx.doi.org/10.12688/f1000research.6896.1 Text en Copyright: © 2015 Zhao CY and Murrell DF http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Zhao, Cathy Y.
Murrell, Dedee F.
Advances in understanding and managing bullous pemphigoid
title Advances in understanding and managing bullous pemphigoid
title_full Advances in understanding and managing bullous pemphigoid
title_fullStr Advances in understanding and managing bullous pemphigoid
title_full_unstemmed Advances in understanding and managing bullous pemphigoid
title_short Advances in understanding and managing bullous pemphigoid
title_sort advances in understanding and managing bullous pemphigoid
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754018/
https://www.ncbi.nlm.nih.gov/pubmed/26918143
http://dx.doi.org/10.12688/f1000research.6896.1
work_keys_str_mv AT zhaocathyy advancesinunderstandingandmanagingbullouspemphigoid
AT murrelldedeef advancesinunderstandingandmanagingbullouspemphigoid

Ejemplares similares